WORLD EXPERT ON LIVER DISEASE JOINS MEDGENICS
December 07 2009 - 2:00AM
UK Regulatory
TIDMMEDG
RNS Number : 6537D
Medgenics Inc
07 December 2009
WORLD EXPERT ON LIVER DISEASE JOINS THE SCIENTIFIC
ADVISORY BOARD OF
MEDGENICS
DR BRUCE BACON TO SUPPORT DEVELOPMENT OF COMPANY'S INNOVATIVE
HEPATITIS-C
TREATMENT
Misgav, Israel and London, UK - 07 December 2009 - Medgenics (AIM: MEDG and
MEDU), the biopharmaceutical company that creates implantable therapeutic
protein producing Biopumps announced today that Dr. Bruce R. Bacon was appointed
to the Scientific Advisory Board of the Company.
Dr. Bacon is a former President of the American Association for the Study of
Liver Diseases (AASLD) and a recognised World expert on Hepatitis. Dr. Bacon is
the James F. King, MD Endowed Chair in Gastroenterology, Professor of Internal
Medicine, and Director of the Division of Gastroenterology and Hepatology at
Saint Louis University School of Medicine in St. Louis, Missouri. The potential
treatment of Hepatitis using the Company's patented INFRADURE technology is one
of the core projects that the Company is seeking to commercialise. Medgenics
reported consistently promising and unprecedented results from the safety and
efficacy clinical trial of its EPODURE Biopumps for sustained anaemia treatment
from a single administration, in progress since September 2008. Biopumps are
made from tissue taken by needle biopsy taken from under the patient's own skin
and processed to become implantable biofactories to provide the required
therapeutic protein for many months. The INFRADURE technology has been similarly
used to create implantable Biopumps that produce Interferon Alpha for months and
will offer a significant addition to the physician's Hepatitis armamentarium to
treat this scourge of a disease.
Dr. Eugene Bauer, Chairman of Medgenics commented:
"We are delighted to welcome Dr. Bacon to Medgenics. As one of the world's top
experts in Hepatitis C, he brings a wealth of experience and influence to the
company. Hepatitis is one of the core areas of treatment that we are seeking to
commercialise. Having an expert of Dr. Bacon's calibre is essential as we move
into the clinic with the exciting new approach to treatment that our INFRADURE
technology offers. Our ability to attract leading figures such as Dr. Bacon
demonstrates the growing stature of Medgenics in the global market for
therapeutic protein delivery. I and the rest of the Board look forward to
working with him as we continue to develop Medgenics."
Dr. Andrew Pearlman, CEO of Medgenics commented:
"The appointment of Dr. Bacon is another important addition to the senior team
at Medgenics. Coming in the wake of the signing of a hemophilia development
agreement with a major international biopharmaceutical company, Dr. Bacon's
appointment is a further strong vote of confidence for Medgenics and our
INFRADURE approach to interferon alpha therapy in the treatment of Hepatitis C."
For further information contact:
+--------------------------------------+--------------------------------------+
| Medgenics, Inc. | Phone: +972 4 902 8900 |
| Dr. Andrew L. Pearlman | |
| | |
+--------------------------------------+--------------------------------------+
| Grayling (Financial PR - UK) | Phone: +44 7900 053 536 |
| Jonathan Shillington | jonathan.shillington@uk.grayling.com |
| Alistair Scott | |
| | |
+--------------------------------------+--------------------------------------+
| Grayling (Investor Relations - US) | Phone: +1 646 284 9472 |
| Leslie Wolf-Creutzfeldt | lwolf-creutzfeldt@hfgcg.com |
| | |
+--------------------------------------+--------------------------------------+
| Blomfield Corporate Finance Limited | Phone: +44207 444 0500 |
| (Nominated Adviser) | |
| James Pinner | |
| Alan MacKenzie | |
| | |
+--------------------------------------+--------------------------------------+
| SVS Securities plc (Broker) | Phone: +44 207 638 5600 |
| Ian Callaway | |
| | |
+--------------------------------------+--------------------------------------+
About Medgenics:
Medgenics is a clinical-stage biopharmaceutical company developing its unique
tissue-based Biopump platform technology using the patient's own skin to provide
sustained-action protein therapy for the treatment of a range of chronic
diseases. The Company currently has three products in development based on this
technology and addressing the indications of:
- Anaemia - using EPODURE, a Biopump producing erythropoietin (EPO)
- Hepatitis-C - using INFRADURE - a Biopump producing interferon-alpha (IFN-a)
- Hemophilia - using a Biopump to produce clotting Factor VIII
The Company's Phase I/II clinical trial using EPODURE to treat anaemia in
patients with chronic kidney disease, has demonstrated proof of concept of the
Biopump. Designed to produce and deliver a therapeutic dose of EPO steadily for
six months or more, EPODURE Biopumps have already provided effective anaemia
treatment in most of these patients for 6-12 months, even at the low
administered dose.
Medgenics intends to develop its innovative products and bring them to market
via multiple strategic partnerships with major pharmaceutical and/or medical
device companies. In addition to treatments for Anaemia, Hepatitis-C,
Hemophilia, Medgenics plans to develop and/or out-license a pipeline of future
Biopump products targeting the large and rapidly growing global protein therapy
market, which is forecast to reach US $87 billion by 2010. Other potential
applications of Biopumps producing various proteins include multiple sclerosis,
arthritis, pediatric growth hormone deficiency, obesity, and diabetes.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUUGCCPUPBPGQ
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024
